-
公开(公告)号：US10981867B2
公开(公告)日：2021-04-20
申请号：US16571896
申请日：2019-09-16
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Marianne Carlsen , Shuai Chen
IPC分类号： C07D209/08 , C07D403/12 , C07D405/14 , C07D401/12 , C07D405/12 , C07D409/12 , C07D487/08 , C07D471/08 , C07D417/12 , A61P35/00 , A61P31/20 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , C07D277/62 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D417/10 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107
摘要： The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
公开(公告)号：US09856214B2
公开(公告)日：2018-01-02
申请号：US15036211
申请日：2014-11-14
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Venkata Velvadapu
IPC分类号： A61K31/405 , A61K31/41 , A61K31/42 , C07D209/42 , C07D401/00 , C07D403/00 , C07D207/327 , C07C229/56 , C07C255/54 , C07C255/55 , C07C211/27 , C07C217/84 , C07C233/11 , C07C233/64 , C07C233/65 , C07C235/58 , C07C311/08 , C07C311/16 , C07C311/17 , C07C317/14 , C07D235/06 , C07D403/10 , C07D239/26 , C07D409/10 , C07D417/10 , C07D471/04 , C07D487/04 , C07D209/08 , C07D295/155 , C07D213/55 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C229/64 , C07C317/44 , C07D207/08 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/70 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D249/06 , C07D277/30 , C07D307/79 , C07D333/54 , C07D401/04 , C07D401/10
CPC分类号： C07D207/327 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C211/27 , C07C217/84 , C07C229/56 , C07C229/64 , C07C233/11 , C07C233/64 , C07C233/65 , C07C235/58 , C07C255/54 , C07C255/55 , C07C311/08 , C07C311/16 , C07C311/17 , C07C317/14 , C07C317/44 , C07C2601/02 , C07D207/08 , C07D207/12 , C07D207/14 , C07D207/16 , C07D209/08 , C07D211/70 , C07D213/55 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D235/06 , C07D239/26 , C07D249/06 , C07D277/30 , C07D295/155 , C07D307/79 , C07D333/54 , C07D401/04 , C07D401/10 , C07D403/10 , C07D409/10 , C07D417/10 , C07D471/04 , C07D487/04
摘要： The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.
-
公开(公告)号：US20240246909A1
公开(公告)日：2024-07-25
申请号：US18408389
申请日：2024-01-09
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Marianne Carlsen , Shuai Chen
IPC分类号： C07D209/08 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , A61P31/20 , A61P35/00 , C07D277/62 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/107
CPC分类号： C07D209/08 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , A61P31/20 , A61P35/00 , C07D277/62 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/107
摘要： The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
公开(公告)号：US20200181078A1
公开(公告)日：2020-06-11
申请号：US16519590
申请日：2019-07-23
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Venkata Velvadapu
IPC分类号： C07D207/327 , C07D401/10 , C07D401/04 , C07D333/54 , C07D307/79 , C07D277/30 , C07D249/06 , C07D231/12 , C07D215/14 , C07D213/74 , C07D213/64 , C07D211/70 , C07D207/16 , C07D207/14 , C07D207/12 , C07D207/08 , C07C317/44 , C07C229/64 , C07C65/28 , C07C65/19 , C07C63/66 , C07C53/18 , C07D213/55 , C07D295/155 , C07D209/08 , C07D487/04 , C07D471/04 , C07D417/10 , C07D409/10 , C07D239/26 , C07D403/10 , C07D235/06 , C07C317/14 , C07C311/17 , C07C311/16 , C07C311/08 , C07C235/58 , C07C233/65 , C07C233/64 , C07C233/11 , C07C217/84 , C07C211/27 , C07C255/55 , C07C255/54 , C07C229/56 , A61K31/44 , A61K31/192 , A61K31/496 , A61K31/4439 , A61K31/404
摘要： Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
-
公开(公告)号：US10442763B2
公开(公告)日：2019-10-15
申请号：US15571223
申请日：2016-05-14
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Marianne Carlsen , Shuai Chen
IPC分类号： C07D209/08 , C07D403/12 , C07D405/14 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D471/08 , C07D487/08 , A61P35/00 , A61P31/20 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , C07D277/62 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D417/10 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107
摘要： The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
公开(公告)号：US10421718B2
公开(公告)日：2019-09-24
申请号：US15814600
申请日：2017-11-16
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Venkata Velvadapu
IPC分类号： A61K31/195 , A61K31/405 , A61K31/41 , A61K31/42 , A61K31/415 , A61K31/40 , C07D207/327 , A61K31/404 , A61K31/4439 , A61K31/496 , A61K31/192 , A61K31/44 , C07C229/56 , C07C255/54 , C07C255/55 , C07C211/27 , C07C217/84 , C07C233/11 , C07C233/64 , C07C233/65 , C07C235/58 , C07C311/08 , C07C311/16 , C07C311/17 , C07C317/14 , C07D235/06 , C07D403/10 , C07D239/26 , C07D409/10 , C07D417/10 , C07D471/04 , C07D487/04 , C07D209/08 , C07D295/155 , C07D213/55 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C229/64 , C07C317/44 , C07D207/08 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/70 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D249/06 , C07D277/30 , C07D307/79 , C07D333/54 , C07D401/04 , C07D401/10
摘要： Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
-
公开(公告)号：US11912659B2
公开(公告)日：2024-02-27
申请号：US17232511
申请日：2021-04-16
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Marianne Carlsen , Shuai Chen
IPC分类号： C07D209/08 , C07D403/12 , C07D405/14 , C07D401/12 , C07D405/12 , C07D409/12 , C07D487/08 , C07D471/08 , C07D417/12 , A61P35/00 , A61P31/20 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , C07D277/62 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D417/10 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107
CPC分类号： C07D209/08 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , A61P31/20 , A61P35/00 , C07D277/62 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/107
摘要： The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
公开(公告)号：US20220396551A1
公开(公告)日：2022-12-15
申请号：US17558877
申请日：2021-12-22
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Venkata Velvadapu
IPC分类号： C07D207/327 , A61K31/404 , A61K31/4439 , A61K31/496 , A61K31/192 , A61K31/44 , C07C229/56 , C07C255/54 , C07C255/55 , C07C211/27 , C07C217/84 , C07C233/11 , C07C233/64 , C07C233/65 , C07C235/58 , C07C311/08 , C07C311/16 , C07C311/17 , C07C317/14 , C07D235/06 , C07D403/10 , C07D239/26 , C07D409/10 , C07D417/10 , C07D471/04 , C07D487/04 , C07D209/08 , C07D295/155 , C07D213/55 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C229/64 , C07C317/44 , C07D207/08 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/70 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D249/06 , C07D277/30 , C07D307/79 , C07D333/54 , C07D401/04 , C07D401/10
摘要： Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
-
公开(公告)号：US20200239415A1
公开(公告)日：2020-07-30
申请号：US16571896
申请日：2019-09-16
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Marianne Carlsen , Shuai Chen
IPC分类号： C07D209/08 , A61K31/422 , C07D401/10 , C07D471/04 , A61K31/541 , A61K31/437 , A61K31/41 , A61K31/501 , A61K31/427 , C07D403/14 , C07D277/62 , A61K31/4155 , A61K31/519 , C07D417/10 , A61K31/551 , A61K31/496 , C07D403/12 , A61K31/4375 , C07D401/12 , C07D413/10 , A61K45/06 , A61K31/4725 , C07D417/12 , C07D491/107 , A61K31/4439 , C07D403/10 , C07D401/14 , C07D487/04 , A61K31/435 , A61K31/404 , A61K31/5377 , A61K31/506 , A61K31/454 , A61P35/00 , C07D471/08 , A61K31/517 , C07D471/10 , A61P31/20 , A61K31/433 , C07D409/12 , C07D487/08 , A61K31/426 , C07D405/12 , C07D405/14
摘要： The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
公开(公告)号：US20180305312A1
公开(公告)日：2018-10-25
申请号：US15571223
申请日：2016-05-14
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Marianne Carlsen , Shuai Chen
IPC分类号： C07D209/08 , A61K31/5377 , C07D405/12 , A61K31/404 , C07D471/04 , A61K31/437 , A61K31/541 , A61K31/4375 , C07D405/14 , A61K31/454 , C07D401/14 , C07D409/12 , A61K31/496 , C07D403/10 , A61K31/41 , C07D413/10 , A61K31/422 , A61K31/501 , C07D401/10 , A61K31/4725 , C07D403/14 , C07D401/12 , A61K31/4439 , C07D403/12 , A61K31/506 , A61K31/4155 , C07D277/62 , A61K31/426 , C07D491/107 , A61K31/435 , C07D417/10 , A61K31/427 , A61K31/433 , A61K31/517 , A61K31/519 , A61K31/551 , C07D487/04 , C07D471/10 , A61K45/06 , A61P31/20
CPC分类号： C07D209/08 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , A61P31/20 , A61P35/00 , C07D277/62 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/107
摘要： The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.024 秒)
